Kenneth Burhop, Ph.D., the former chief scientific officer at Sangart, Inc., has joined Integra LifeSciences Holding Corporation as corporate vice president and chief scientific officer. He is the author of over 40 publications, 70 abstracts and is the holder of multiple patents, according to a company press release. Burhop will lead the company’s portfolio prioritization and management, as well as the scientific evaluation of corporate development and new product opportunities.
Burhop Joins Integra LifeSciences
1 min read Premium comments
“I am excited to join Integra to lead our R&D efforts and advance our growth strategy forward, ” Burhop said. “We have an opportunity to develop and commercialize exciting new technologies in regenerative medicine, as well as optimize our overall portfolio management across our business segments.”
Prior to his work at Sangart, Inc., Burhop spent 20 years in various leadership positions at Baxter Healthcare Corporation.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.